Mal-PEG2-MMAE acts as a drug-linker conjugate for ADC (antibody-drug conjugate) development. The maleimide can conjugate with cysteine-containing molecules, while MMAE is a synthetic antineoplastic agent that may be employed as an ADC payload to target tumor cells. The hydrophilic PEG linker imparts water solubility.
Usually ships within 24 hours.